Showing 1231-1240 of 1539 results for "".
- AMA: New CPT Code to Report Novel Coronavirus Testhttps://practicaldermatology.com/news/ama-new-cpt-code-to-report-novel-coronavirus-test/2460307/The Current Procedural Terminology (CPT®)Editorial Panel has approved a new addition to the CPT code set to report testing for the virus that causes COVID-19. The American Medical Association (AMA) says the code will help streamline data-driven resource and allocation planning in t
- Cynosure's Four-Mode RF Microneedling Device Cleared for Marketinghttps://practicaldermatology.com/news/cynosures-four-mode-rf-microneedling-device-cleared-for-marketing/2460289/The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device. The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Survey: Many Men Don’t Wash Their Faces Every Dayhttps://practicaldermatology.com/news/survey-many-men-dont-wash-their-faces-every-day/2460266/One-third of men admit to not washing their faces daily, according to a poll of 1,000 men aged 18 and older conducted by AcuPoll for Tiege Hanley. The Men’s Skin Care Survey by Tiege Hanley found that younger men are more likely to drop the
- FDA Follow-Up Study: Sunscreen Active Ingredients Are Absorbed by Bloodstreamhttps://practicaldermatology.com/news/fda-follow-up-study-sunscreen-active-ingredients-are-absorbed-by-bloodstream/2460258/Six active ingredients administered in four different sunscreen formulations are systemically absorbed, according to a new report. The study was sponsored by U.S. Food and Drug Administration (FDA) and is a follow-up to a May 2019 study that generated a lot of headlines. The new report
- Study of Victoria's Secret Models Highlights Changing and Unattainable Beauty Standardshttps://practicaldermatology.com/news/study-of-victorias-secret-models-highlights-changing-and-unattainable-beauty-standards/2460242/While the average American woman's waist circumference and dress size has increased over the past 20 years, Victoria's Secret fashion models have become more slender, with a decrease in bust, waist, hips and dress size, though their waist to hip ratio (WHR) has remained constant, accordin
- Avita Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System in Vitiligohttps://practicaldermatology.com/news/avita-medical-receives-us-fda-investigational-device-exemption-approval-of-clinical-feasibility-study-to-evaluate-recell-system-in-vitiligo/2460240/The U.S. Food and Drug Administration (FDA) approved AVITA Medical’s Investigational Device Exemption (IDE) application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL Autologous Cell Harvesting Device (RECELL System) for repigmentation of depigmen
- FDA Approves Ortho Dermatologic’s Arazlo Lotion for Acnehttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-arazlo-lotion-for-acne/2460238/The FDA has approved the New Drug Application for ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. Ortho Dermatologic’s ARAZLO is the first tazarotene acne treatment available in a lotion form,
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres